Andere talen Hyloris Pharmaceuticals SA

Aandelen

HYL

BE0974363955

Farmaceutische producten

Real Time Euronext Bruxelles Andere beurzen 09:46:21 10-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,020 ^EUR	+0,33%		-0,99%	-7,95%

23/11	Farmazwaargewichten helpen Bel20 schade beperken	AM
19/11	Hyloris Pharmaceuticals benoemt co-CEO tot enige Chief Executive Officer	MT

Andere talen

Hyloris Pharmaceuticals Appoints Co-CEO as Sole Chief Executive	19/11
Hyloris Pharmaceuticals : Board of Directors appoints Stijn Van Rompay as CEO	19/11
Hyloris Pharmaceuticals : Inside Information Hyloris Board of Directors appoints Stijn Van Rompay as CEO ENGLISH VERSION	19/11
Hyloris Pharmaceuticals : Inside Information Hyloris Board of Directors appoints Stijn Van Rompay as CEO FRENCH VERSION	19/11
Hyloris Pharmaceuticals : Announces Positive Clinical Study Results for IV Aspirin	14/11
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Positive Clinical Study Results for IV Aspirin ENGLISH VERSION	14/11
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Positive Clinical Study Results for IV Aspirin FRENCH VERSION	14/11
Hyloris Pharmaceuticals : Inside Information Hyloris and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets ENGLISH VERSION	28/10
Hyloris Pharmaceuticals : Inside Information Hyloris and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets FRENCH VERSION	28/10
Hyloris Pharmaceuticals : and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets	28/10
Hyloris Pharmaceuticals Wins Exclusive Chinese Licensing, Distribution Deal for Iron Deficiency Anemia Treatment	27/10
Hyloris Pharmaceuticals : Announces Partnership with Grand Life Sciences Group for HY-094 in China	27/10
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Grand Life Sciences Group for HY-094 in China ENGLISH VERSION	27/10
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Partnership with Grand Life Sciences Group for HY-094 in China FRENCH VERSION	27/10
Hyloris Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2025	25/09
Hyloris Pharmaceuticals : 2025 Rapport Semestriel - Français	25/09
Consolidated 2025 Half-Year Results and Outlook: Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position	25/09
Hyloris Pharmaceuticals : 2025 Half-Year Report - English	25/09
Hyloris Pharmaceuticals : KBCS' Life Sciences Conference Brussels	25/09
Hyloris Pharmaceuticals : Inside Information Hyloris Pharmaceuticals Reports 2025 Half-Year Results and Provides Business Outlook ENGLISH VERSION	25/09
Hyloris Pharmaceuticals : Inside Information Hyloris Pharmaceuticals Reports 2025 Half-Year Results and Provides Business Outlook FRENCH VERSION	25/09
Hyloris Pharmaceuticals : Inside Information Hyloris Signs Exclusive Licensing Agreement with Huons Co., Ltd. for XTRAZA™ in South Korea ENGLISH VERSION	22/08
Hyloris Pharmaceuticals : Inside Information Hyloris Signs Exclusive Licensing Agreement with Huons Co., Ltd. for XTRAZA™ in South Korea FRENCH VERSION	22/08
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Positive Clinical Study Results for Atomoxetine Oral Solution ENGLISH VERSION	17/07
Hyloris Pharmaceuticals : Inside Information Hyloris Announces Positive Clinical Study Results for Atomoxetine Oral Solution FRENCH VERSION	17/07

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hyloris Pharmaceuticals SA

Aandelen

HYL

BE0974363955

Farmaceutische producten

Andere talen

Filters